0000000000447720

AUTHOR

Irène Juhan-vague

showing 2 related works from this author

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the A…

2007

Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UF…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up StudiesJournal of thrombosis and haemostasis : JTH
researchProduct

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery di…

2008

Summary. Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD. Patients/Methods: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed. Results: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuri…

MaleRiskCarboxypeptidase B2medicine.medical_specialtymedicine.medical_treatmentCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionAgedProportional Hazards Modelsbusiness.industryUnstable anginaProportional hazards modelHazard ratioHematologyMiddle Agedmedicine.diseaseCarboxypeptidase BDeath Sudden CardiacCohortCardiologyFemalebusinessProtein Cmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct